ANNEXON, INC. Accounts Payable
ANNEXON, INC. (ANNX) had Accounts Payable of $15.73 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-12
- 2026-06-30: Accounts Payable, Current $15.73M.
- 2026-03-31: Accounts Payable, Current $17.53M.
- 2025-12-31: Accounts Payable, Current $14.93M.
- 2025-09-30: Accounts Payable, Current $18.22M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $15.73M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $17.53M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $14.93M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $18.22M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $11.52M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $10.44M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $10.43M 10-K · filed 2026-03-30 |
| 2024-09-30 | $6.75M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $4.13M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $3.97M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $5.49M 10-K · filed 2025-03-03 |
| 2023-09-30 | $4.81M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $7.16M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $10.35M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $7.42M 10-K · filed 2024-03-26 |
| 2022-09-30 | $6.92M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $10.30M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $9.38M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $11.15M 10-K · filed 2023-03-06 |
| 2021-09-30 | $4.80M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $4.18M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $4.52M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $3.73M 10-K · filed 2022-03-01 |
| 2020-09-30 | $3.95M 10-Q · filed 2020-11-16 |
| 2020-06-30 | $3.06M 10-Q · filed 2020-09-08 |
| 2019-12-31 | $2.37M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |